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Piplartine (PPTN) is an alkaloid amide found in Piper species that presents different activities. PPTN determination in rat plasma 
is necessary to better understand its biological effects. The aim of this study was to develop a sensitive LC-MS/MS method for the 
determination of PPTN in rat plasma. The performance criteria for linearity, sensitivity, precision, accuracy, recovery, and stability 
have been assessed and were within the recommended guidelines. The validated method proved to be suitable in a pilot study of PPTN 
kinetic disposition in rat plasma after a single intraperitoneal dose, and represents an appropriate tool to further pharmacokinetic 
studies.
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INTRODUCTION
Focus on plant research has recently increased all over the world, 
and a large body of evidence has been collected showing the immense 
potential of medicinal plants used in traditional medicine.1 People in 
separate cultures and places are known to have used the same plants 
for similar medical problems. A larger number of these plants and 
their isolated constituents have shown beneficial therapeutic effects, 
including antioxidant, anti-inflammatory, anticancer, antimicrobial, 
and immunomodulatory effects.2
Piper species (Piperaceae) are distributed widely in the tropical 
and subtropical regions of the world. They are used not only in human 
dietaries, as spice, but also for other purposes such as a preservative, in 
perfumery, and have multiple applications in different folk medicines, 
including the Indian Ayurvedic system, and have been reported to 
possess numerous biological activities.3 In particular, they are useful 
against asthma, bronchitis, fever, hemorrhoid diseases, gastrointesti-
nal diseases, and rheumatism. The preparations obtained from plants 
belonging to the genus Piper have shown anti-inflammatory, antifee-
dant, insecticidal, and antihypertensive activities, as well as anticancer 
properties.4 Phytochemical investigations of Piper species have led to 
the isolation of several classes of physiologically active compounds 
such as alkaloids, amides, pyrones, terpenes, steroids, kawapyrones, 
piperolides, flavonoids, phenylpropanoids, lignans and neolignans.4 
Several of these phytochemicals have significant  biological activity, 
including alkaloid amides, such as piplartine (PPTN, Figure 1).
Previous studies have emphasized that phytochemicals isolated 
from spices have great pharmacological potential.5 In fact, PPTN, a 
known alkaloid amide isolated from the Piper species shows several 
pharmacological activities. It has been reported that this alkaloid has 
cytotoxic,5,6 antifungal,7 anti-platelet aggregation,8 antitumoral,5,6 
anxiolytic and antidepressant,9 antileishmanial,10 and genotoxic11 
activities. Only one HPLC method has been described in the literature 
for the quantitative determination of PPTN in plants in natura, in 
plantlets in vitro and ex vitro, and in callus of Piper tuberculatum.12 In 
spite of the cited pharmacological potential, no previous investigations 
reporting PPTN determination in plasma are available in the literature.
Pharmacokinetic data are crucial to better understand the biologi-
cal effects of new compounds. No information is currently available 
on the absorption, distribution, metabolism or excretion of PPTN. 
In this work, a method is presented for the determination of PPTN 
in rat plasma samples using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Prior to verifying the reliability of the 
bioanalytical method for application in the pilot pharmacokinetic 
studies, it was rigorously validated in accordance with United States 
Food and Drug Administration (FDA) guidelines.13 Thus, the lineari-
ty, recovery, limit of quantification, precision, accuracy and sample 
stability were determined. The applicability of the validated method 
was tested using plasma samples obtained after a single intraperitoneal 
Figure 1. Chemical structures of pirplatine (PPTN) and carbamazepine (IS)
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administration of 50 mg kg-1 PPTN to Wistar rats. To our knowledge, 
this is the first bioanalytical method for PPTN analysis and its ap-
plication in a pilot study of PPTN kinetic disposition in rat plasma.
EXPERIMENTAL
Chemicals and reagents
PPT was obtained from the roots of Piper tuberculatum as des-
cribed previously.9 Briefly, 420.0 g of ground roots of P. tuberculatum 
was macerated with a mixture of diethyl ether: ethyl acetate (1:1, v/v, 
1.5 L) for 24 h (for three times). The solvent mixture was evaporated 
under reduced pressure to yield a yellowish solid (13.24 g), which 
provided PPTN (4.35 g) after crystallization from methanol. After 
being characterized, specifically by m.p. 122.2-122.6 °C, 1D and 
2D NMR analyses and MS/MS, the PPTN was considered a pure 
compound (data not shown). Carbamazepine, used as the internal 
standard (IS), was purchased from Sigma (St. Louis, MO, USA).
Acetonitrile HPLC grade was obtained from Tedia (Fairfield, OH, 
USA). Methanol was purchased from Burdick & Jackson (Muskegon, 
MI, USA). Glacial acetic acid diethyl ether and ethyl acetate were pur-
chased from J. T. Baker (Phillipsburg, NJ, USA). Toluene analytical 
grade was obtained from Mallinckrodt Baker Inc. (Phillipsburg, NJ, 
USA). The water used in all experiments was purified on a Milli-Q 
Plus System (Millipore, Bedford, MA, USA). All others reagents 
were of analytical grade at the highest purity available. 
Instrumentation and LC-MS/MS conditions
Experiments were performed on HPLC equipment from Shimadzu 
(Kyoto, Japan) consisting of two LC10AD solvent pumps, an SLC 
10A system controller, a CTO-10AS column oven and a 20 µL loop 
with a Rheodyne model 7125 injector (Cotati, CA, USA). An NST 18 
analytical column (250 × 4.6 mm id, 5 µm particle size) obtained from 
Nanoseparation Technologies (São Paulo, SP, Brazil) protected by a 
LiChrospher® 100 RP18 guard column (4 x 4 mm id, 5 mm particle 
size) obtained from Merck (Darmstadt, Germany) was used for the 
development and validation of the method. The mobile phase consisted 
of acetonitrile: water (70:30, v/v) plus 0.2% of acetic acid delivered 
isocratically at 1.0 mL min-1. The mobile phase was degassed on-line 
using high purity helium gas. The HPLC eluent was split by a Valco 
valve and a flow rate of approximately 0.2 mL min-1 was introduced 
into the stainless steel capillary probe of the mass spectrometer.
All experiments were conducted using a Quattro LC triple 
quadrupole mass spectrometer instrument (Micromass, Manchester, 
UK). Ions were generated using an electrospray ionization interface 
(ESI) and detected in the positive ion mode. Nitrogen was used as 
the desolvation and nebulizing gas at flow rates of 265 and 27 L h-1, 
respectively. Argon was used as the collision gas, at a collision cell 
pressure of 1.85 x 10-3 mbar. The source block and desolvation tem-
peratures were 100 and 250 ºC, respectively. In order to establish the 
most MS/MS sensitive operating conditions, parameters optimization 
were performed by direct infusion of PPTN standard solution (10 µg 
mL-1) and IS prepared in the mobile phase, into the MS throught a 
Syringe Pump (Micromass, Manchester, UK) at a flow rate of 20 µL 
min-1. The optimized ESI-MS conditions for positive ion mode ope-
ration resulted in the capillary voltage of 3.0 kV where the sampling 
cone voltage was maintained at 15 V for PPTN and at 20 V for IS. 
The collision energy was 10 eV for PPTN and 20 eV for the IS. The 
analyses were performed in the multiple reaction monitoring (MRM) 
mode by monitoring the ion transitions from m/z 317.4 > 220.9 for 
parent molecule [M+H]+ and daughter ion of PPTN and m/z 236.4 > 
193.8 for the IS, collected with a dwell time of 0.4 s. The instrumen-
tation was controlled and data were collected and processed, using 
Micromass Masslynx 3.0 software (Manchester, UK).
Stock solution and calibration standards
A stock solution of PPTN was prepared at 1 mg mL-1 in me-
thanol. Quality controls (QC) and calibration standards were ob-
tained by serial dilution of the stock solution with methanol. The 
calibration standards were 0.016, 0.08, 0.16, 0.4, 0.8, 2.0, 5.0, 10.0 
and 20.0 µg mL-1. Spiked rat plasma samples were obtained by the 
addition of 25 µL of these standard solutions to 0.2 mL of drug-free 
rat plasma prior to extraction, resulting in final PPTN plasmatic 
concentrations: 2.0, 10.0, 20.0, 50.0, 100.0, 250.0, 625.0, 1250.0, and 
2500.0 ng mL-1, respectively. Plasma QC samples spiked with 20.0, 
625.0, and 1250.0 ng mL-1 were prepared to evaluate the accuracy 
and precision of the method. For the stability study, the QC samples 
were prepared at the concentrations of 20.0 and 1250.0 ng mL-1 of 
PPTN. The IS solution was prepared in methanol at the concentration 
of 5.0 µg mL-1 and aliquots of 25 µL were added to samples prior 
to extraction, resulting in a plasma concentration of 125.0 ng mL-1. 
All standard solutions were stored frozen at −20 ºC until analysis 
and protected from light, remaining stable for at least two months.
Sample preparation
PPTN was extracted from rat plasma by a liquid–liquid extraction 
(LLE) procedure employing toluene as the extractor solvent. After 
thawing at room temperature, aliquots of 0.2 mL of rat plasma, 
25 µL of IS (5.0 µg mL-1) and 1.0 mL of toluene were transferred 
to amber tubes and submitted to horizontal mechanical shaking for 
30 min. The samples were then centrifuged at 2000 x g for 10 min. 
The organic phases were collected and evaporated to dryness under 
a gentle stream of compressed air. All these steps were carried out at 
room temperature (22 ± 2 ºC). The residues were dissolved in 50 µL 
of the mobile phase by vortex for 20 s and an aliquot of 20 µL was 
injected into the LC-MS/MS. During all operations, the samples were 
protected from light in order to avoid photo-degradation of PPTN.
Animals
Young healthy male Wistar rats (body weight 220 ± 10 g) pro-
vided the blank biological matrices used for calibration curves and 
QC sample preparation, and also for method application. Animals 
were obtained from the Central Animal House of the University of 
São Paulo (Ribeirão Preto, SP, Brazil) and from the Central Animal 
House of Federal University of Ceará (Fortaleza, CE, Brazil) for the 
obtention of drug-free plasma samples and for method application, 
respectively. Animals were housed under standard conditions in a 
limited access area and maintained in a reverse 12 h light–dark cycle 
(lights on at 6:00 a.m.). The animals were treated according to the 
ethical principles of animal experimentation of the Brazilian Colle-
ge of Animal Research (COBEA, CE, Brazil). The Animal Studies 
Committee of the Federal University of Ceará (Fortaleza, CE, Brazil) 
approved the experimental protocols under code UFC 45/05. To obtain 
plasma, rat blood samples were collected in heparinized tubes from 
the retro-orbital venous plexus, centrifuged at room temperature at 
2000 x g for 10 min and stored at −20 ºC.
Method validation
The analytical method validation for the determination of PPTN 
in rat plasma was performed according to the guidance of Bioa-
nalytical Method Validation of the United States Food and Drug 
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Administration (FDA).13 The validation parameters evaluated were: 
linearity, sensitivity (limit of quantification, LOQ), recovery, accuracy, 
precision and stability of PPTN in plasma samples. Coefficients of 
variation (CV%) and relative error (RE%) percentages less than 15% 
were considered acceptable, except for the LOQ, whose values were 
extended to 20%, as recommended for the analysis of biological 
samples for pharmacokinetic studies.14
Matrix effects
Matrix effects were assessed by comparing the peak areas obtained 
from the analysis of pure standard solutions dissolved in the mobile 
phase with the peak areas acquired from samples of four different lots 
of rats not treated with PPTN. The experiment was done in triplicate 
for the low concentrations of PPTN (2.0 ng mL-1) and also for the 
concentration of the IS used in the developed method (5.0 mg mL-1).
Linearity
The linearity of the method was evaluated by the analysis in tripli-
cate of plasma samples spiked with increasing PPTN concentrations 
matching those employed for the construction of the calibration curve 
(2.0, 10.0, 50.0, 250.0, 500.0 and 1250.0 ng mL-1). The regression 
results were obtained by plotting the peak height ratios of PPTN/IS 
versus nominal concentrations using least-squares linear regression 
analysis with 1/x weighting factor. The relationship between respon-
se and concentration was considered to be linear up to the highest 
concentration analyzed with an error lower than 15% and correlation 
coefficient (r2) ≥ 0.995.
Recovery
The extraction efficiency was determined by comparing peak hei-
ght ratios (PPTN/IS) of known amounts of PPTN in the mobile phase 
(unextracted) directly injected into the analytical column to the peak 
height ratios of plasma samples containing the same amounts of PPTN 
after extraction. The absolute recoveries were assessed at concentrations 
of 20.0, 625.0 and 1250.0 ng mL-1 (n = 3, for each concentration) and 
were expressed as percentage of the amount extracted. Drug-free rat 
plasma samples were also analyzed to assess the capacity of sample 
pretreatment for eliminating endogenous interferences.
Sensitivity
The sensitivity of the method was evaluated through LOQ, which 
was defined as the lowest concentration that could be determined 
with accuracy and precision below 20% over five analytical runs. 
Plasma samples spiked with concentrations as low as 2.0 ng mL-1 
PPTN were analyzed five-fold.
Accuracy and precision
To assess precision and accuracy within-day, replicate analysis 
(n = 5) of QC plasma samples spiked at 20.0, 625.0 and 1250.0 ng mL-1 
PPTN were performed on the same day. For the between-day assay, 
five determinations of each concentration level (as described for 
within-day assay) were analyzed on three consecutive days. Precision 
and accuracy were expressed as coefficient of variation (CV%) and 
relative error (RE%), respectively.
Stability
The stability of PPTN in plasma samples was evaluated by 
testing the influence of freeze (−20 ºC) and thaw (22 ± 2 ºC) cycles 
and short-term room temperature while protected from light. Spiked 
plasma samples were prepared in triplicate (n = 3) at both the low 
(20 ng mL-1) and high concentration (1250 ng mL-1) of the QC sam-
ples. To perform the freeze-thaw cycle stability test, these samples 
were stored at −20 ºC for 24 h and thawed at room temperature. When 
completely thawed, the samples were refrozen for 12 h under the 
same conditions. The freeze-thaw cycle was repeated a further two 
times, and then the samples were analyzed on the third cycle. The 
short-term room temperature stability test was assessed by analyzing 
samples that were kept on the bench-top for 4 h at room temperature 
(22 ± 2 ºC). After this period, all the samples were analyzed on the 
same day. The peak height ratios (PPTN/IS) obtained from the sta-
bility tests were compared to the peak height ratios obtained from 
freshly prepared samples. Student’s t-test was applied, with the level 
of significance set at p ≤ 0.05.
Application of the method
To assess the applicability of the validated method, two groups 
of six young healthy male Wistar rats were treated intraperitoneally 
with 50 mg kg-1 of PPTN dissolved in a mixture of water: DMSO 
(9:1, v/v). The dose and route of administration of PPTN was 
selected based on previous results obtained by our group.10 The 
control group consisted of three rats that received water instead of 
PPTN solution. After administration, retro-orbital venous plexus 
blood samples were collected from the rats into heparinized tubes 
at 30 min, 3 and 24 h (three animals for each time interval). Plasma 
fraction samples were separated and kept at −20 ºC until analysis. 
The samples and an extracted calibration curve were analyzed 
simultaneously by the LC-MS/MS method for the determination 
of PPTN concentration in rat plasma.
RESULTS AND DISCUSSION
Optimization of the LC-MS-MS method
In order to establish the most sensitive MS/MS operating con-
ditions, parameters optimization were performed by direct infusion 
of PPTN and IS standard solutions (10.0 mg mL-1) prepared in the 
mobile phase into the MS through a syringe pump at a flow rate 
of 20 µL min-1. The optimization of MS detection was carried out 
in the electrospray (ESI) positive ion mode due to the amide in 
the PPTN and carbamazepine (IS) chemical structures. The cone 
voltage yielded best results at 15 V for PPTN and at 20 V for the 
IS. The product ions were generated through fragmentation of the 
molecular ions by collision-activated dissociation using argon as 
the collision gas. The intensity of a selected product ion peak m/z 
in the MRM mode of each compound was optimized by varying 
the collision energy, which was 10 eV for PPTN and 20 eV for the 
IS. The protonated species [M+H]+ and their respective product 
ions were monitored at 317.4 > 220.9 for PPTN (Figure 2A) and 
236.4 > 193.8 for the IS (Figure 2B).
The resolution of PPTN and IS was obtained by reverse phase 
mode using a C18 analytical column. The composition of mobile pha-
se and the choice of organic modifier was evaluated in terms of peak 
shape, sensitivity at mass detection for analyte/IS, and time analysis. 
The best signal and good ionization was achieved employing a mobile 
phase consisting of a mixture of acetonitrile: water (70:30, v/v) plus 
0.2% of acetic acid at a flow rate of 1.0 mL min-1. These conditions 
allowed adequate resolution in a short analysis time, where IS and 
PPTN were detected at 2.23 and 2.75 min, respectively. To maximize 
ionization efficiency, acetic acid was selected as the proton donator 
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due the presence of amide groups in both analyte and IS molecules and 
its compatibility with the column stationary phase and MS. The addi-
tion of 0.2% of glacial acetic acid to the mobile phase was sufficient 
to obtain a simultaneous positive ion ESI response for PPTN and IS.
Method validation
In preliminary studies, the PPTN solution presented slight 
photo-degradation. Thus all experiments were conducted in amber 
tubes protected from light in order to avoid significant variation in 
the determinations.
The efficiency of th extraction procedure was calculated at 
high, medium and low plasma concentration levels for PPTN and 
the recovery results are given in Table 1. Mean absolute recoveries 
close to 75% indicate that the use of toluene as the extractor solvent 
provided good and satisfactory recovery of PPTN and IS from rat 
plasma samples. In addition, the precision values of CV of between 
1.8 and 3.3% demonstrated very good reproducibility of the LLE 
procedure throughout the whole calibration range.
The selectivity of the method was demonstrated by comparing the 
analysis of plasma samples from four different lots of rats not treated 
with PPTN and checking the potential interfering effect of endoge-
nous compounds on PPTN quantification. Typical chromatograms 
for drug-free rat plasma sample (Figure 3A) and rat plasma spiked 
with PPTN (Figure 3B) and IS (Figure 3C) are shown in Figure 3. No 
endogenous interferences peaks across the retention window of PPTN 
and IS, or metabolite interference during the quantifying of PPTN in 
post-dose samples, was observed. In addition, the selectivity of this 
method was also evaluated in human plasma samples and the results 
observed were the same as those obtained for rat plasma samples.
Acceptable linearity was obtained for PPTN over the concen-
tration range 2.0 to 2500.0 ng mL-1 in rat plasma (r2 = 0.9968). 
The typical least-squares regression line was y = 0.00838139x + 
0.0230658, where y represents the peak height ratios of PPTN and 
IS, and x represents the plasma concentrations of PPTN.
For sensitivity, the LOQ of PPTN in rat plasma was accepted as 
the lowest points on the calibration curve with a CV less than 20% 
for the analysis of PPTN. The LOQs were determined experimen-
tally (n = 5) based upon the linear regression from the established 
linear range of the standard calibration curve. The plasma calibration 
standard of 2.0 ng mL-1 (n = 5) was reliablye quantified with a CV 
of 11.2% and an RE of 5.7%. According to the preliminary results, 
this LOQ is adequate for the purposes of the method.
The within-day and between-day precision and accuracy of the 
method were evaluated by replicate (n = 5) analysis of the same spi-
ked plasma samples series at low, medium and high concentrations 
of PPTN. The precision and accuracy of the method are shown in 
Table 2. The data indicate agreement with FDA recommendations; 
neither CV nor RE exceeded a value of 15%, proving that the assay 
method is reproducible on different days.
Stability was assessed by leaving the QC samples at low and 
high concentrations. The results showed no statistically significant 
differences between freeze–thaw cycles and short-term room tempe-
rature of PPTN in rat plasma samples and freshly spiked samples of 
Figure 2. Tandem mass spectra showing the protonated molecular ion (m/z 
317.42) and the predominant fragment ion (m/z 220.90) for the piplartine (A) 
and for the internal standard, carbamazepine, (m/z 236.40) and its respective 
fragment ion (m/z 193.83), (B) from infusion experiments carried out on the 
mobile phase
Table 1. Mean absolute recovery of the developed method
Plasma concentration 
(ng mL−1, n = 3a)
PPTN
Absolute recovery (%) Precisionb (CV%)
20.0 86.1 2.6
625.0 68.6 1.8
1250.0 72.2 3.3
Mean 75.6 12.2
a
 n, number of samples; b CV, coefficient of variation.
Figure 3. Representative ion chromatograms of (A) blank rat plasma sample 
(Total Ion Current, TIC) and (B) rat plasma sample spiked with piplartine con-
centration at LOQ level (2 ng mL-1) and (C) IS (carbamazepine, 125.0 ng mL-1). 
MRM of m/z 317.42 > 220.90 for piplartine and of m/z 236.40 > 193.83 for 
IS. Chromatographic conditions as in Experimental
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the same concentrations. The results from Student’s t-test (Table 3) 
indicate that repeated freeze-thaw cycles, and after a period for 4 h 
at room temperature (22 ± 2 ºC), do not affect the sample integrity of 
PPTN in rat plasma but these samples should be protected from light.
Method application
This method was developed for the determination of PPTN 
in rat plasma samples using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) to investigate its suitability for pharma-
cokinetic studies. The PPTN plasma concentration was determined 
following intraperitoneal administration of a single dose of 50 mg 
kg-1 to the Wistar rats (n = 3, for each group: 30 min, 3 and 24 h). 
The rat plasma samples were obtained immediately after collecting 
blood samples, three times after administration. Figure 4 depicts 
the chromatograms obtained from samples of rats treated with 
PPTN (pilot study) showing the applicability of the developed and 
validated method. The PPTN mean concentrations founded in rat 
plasma were 1511.9, 418.2 and 41.9 ng mL-1 for 30 min, 3 and 
24 h, respectively.
CONCLUSIONS
The present paper describes for the first time a fast and sensitive 
LC-MS/MS method for the quantification of PPTN in rat plasma. The 
method involved a simple sample preparation technique employing 
LLE with adequate recovery at low plasma volumes and low organic 
solvent consumption. The analyses were easily executed under iso-
cratic chromatographic conditions with an analysis time of less than 
4 min. The performance criteria for linearity, sensitivity, precision, 
accuracy, recovery, and stability have been assessed and were within 
the FDA recommended guidelines. LC-MS/MS in MRM mode is a 
powerful analytical technique for pharmacokinetic investigations 
fulfilling both specificity and selectivity requisites. This method was 
capable of accurately estimating PPTN concentration in rat plasma of 
up to 2.0 ng mL-1 with high reproducibility. Finally, the suitability of 
the method for the determination of PPTN in rat plasma was clearly 
demonstrated in rats after intraperitoneal administration. This first 
validation study represents a relevant contribution to future inves-
tigations of the PPTN pharmacokinetic, which has important and 
manifold pharmacological activities.
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